Pharma & Biotech News , from our Global Correspondents
Refine Search
Pharmaceutical
The Russian pharmaceutical market is showing positive dynamics these days, despite the ever-tightening sanctions regime and the growing isolation of Russia in the international arena, reports The Pharma Letter’s local correspondent. 13 June 2025
Generics
Russian drugmaker Axelpharm has managed to lift the ban on the launch of osimertinib - a drug, which is used in the treatment of lung cancer - in the domestic market, reports The Pharma Letter’s local correspondent. 12 June 2025
Pharmaceutical
In Latin America, the average percentage of the public budget for health is 12.75%, half of what is allocated by the 38 countries that make up the Organization for Economic Cooperation and Development (OECD), which on average is 24.5%. 9 June 2025
Generics
The Russian pharmaceutical market, valued at around $41 billion, continues to be a magnet for Indian pharmaceutical companies. 9 June 2025
Pharmaceutical
Artificial Intelligence (AI) has rapidly evolved from a promising technology to a core enabler of innovation in the pharmaceutical industry. Today, AI is estimated to generate between $350 billion and $410 billion in annual value for pharmaceutical companies. 29 May 2025
Generics
Russian drugmaker Geropharm has received a compulsory license from the Russian state to produce a generic of Ozempic (semaglutide) developed by Denmark’s Novo Nordisk. As in case of Ozempic, Geropharm’s generics are used to treat diabetes, as well as for weight loss, reports The Pharma Letter’s local correspondent. 28 May 2025
Biotechnology
Lupus is a rare autoimmune disease characterized by chronic inflammation. It presents in four main forms: systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), drug-induced lupus, and neonatal lupus. 28 May 2025
Generics
The share of generics in the Russian pharmaceutical market is steadily growing despite the efforts of the local state to create conditions for the production of original drugs, The Pharma Letter’s local correspondent reports. 22 May 2025
Pharmaceutical
Pharmasyntez, one of Russia’s leading drugmakers, plans a significant expansion of its portfolio of innovative drugs in the short-term, according to recent statements, made by representatives of the company, reports The Pharma Letter’s local correspondent. 21 May 2025
Generics
Representatives of Russian patent unions have sent an appeal to the Russian Scientific Center for Expertise of Medical Products to provide a protocol for the compliance of Lantesens, a drug for the treatment for spinal muscular atrophy (SMA), which is produced by the Russian drugmaker Generium, a copy of the original drug Spinraza (nusinersen) from US biotech Biogen, reports The Pharma Letter’s local correspondent. 14 May 2025
Pharmaceutical
The Russian authorities are preparing for a further reduction of the share of imported drugs in the domestic public healthcare system. 13 May 2025
Generics
India has declined the UK's request to include a 'data exclusivity' clause in the proposed Free Trade Agreement (FTA), as announced on May 6, underscoring its commitment to protect its robust domestic generic drug industry. India's generic drug industry is valued at over $30 billion. 13 May 2025
Pharmaceutical
A Feature on M&A, VC investment, licensing and partnerships in the radiopharmaceuticals arena. 9 May 2025
Pharmaceutical
As the US government, under President Donald Trump, is on the verge of announcing significant new tariffs on pharmaceutical imports, Indian drug-maker stocks continue to take a hammering on the bourses. 8 May 2025
Pharmaceutical
The pharmaceutical industry in Latin America is currently facing several challenges in terms of containment of chronic non-communicable diseases, impacted by the lack of adherence to treatments and the delay in access to innovations in diagnosis, treatment, control and follow-up. 2 May 2025
Pharmaceutical
April marks Sarcoidosis Awareness Month - a timely opportunity to highlight recent advances in the treatment of this rare condition. 2 May 2025
Pharmaceutical
Shortly after Robert F Kennedy Jr was sworn in as Secretary of Health and Human Services (HHS), US President Donald Trump issued an executive order establishing the Make America Healthy Again Commission. 1 May 2025
Pharmaceutical
The Russian drugmaker Akrikhin has filed a lawsuit against UK pharma major AstraZeneca to the Moscow Intellectual Property Court asking to recognize its right to use formulas from two patents of Astra Zeneca for production of Forxiga (dapagliflozin), a drug for the treatment of diabetes and cardiovascular diseases, The Pharma Letter’s local correspondent reports. 1 May 2025
Pharmaceutical
The Russian pharmaceutical market grew up to 814 billion roubles ($10 billion) in the first quarter of 2025, 11% higher compared to the same period in 2024, according to latest data, provided by experts of the Russian research agency in the field of pharmaceutics DSM-Group and some local media reports, reports The Pharma Letter’s local correspondent. 30 April 2025
Pharmaceutical
Seeking to ensure the quality and safety of pharmaceutical products, India's regulatory bodies have intensified their crackdown on substandard and spurious drugs. The move comes at a crucial juncture as the country inches closer to establishing a comprehensive regulatory framework for over-the-counter (OTC) medications, reports The Pharma Letter’s India correspondent. 28 April 2025
Pharmaceutical
The Russian pharmaceutical market is showing positive dynamics these days, despite the ever-tightening sanctions regime and the growing isolation of Russia in the international arena, reports The Pharma Letter’s local correspondent. 13 June 2025
Generics
Russian drugmaker Axelpharm has managed to lift the ban on the launch of osimertinib - a drug, which is used in the treatment of lung cancer - in the domestic market, reports The Pharma Letter’s local correspondent. 12 June 2025
Pharmaceutical
In Latin America, the average percentage of the public budget for health is 12.75%, half of what is allocated by the 38 countries that make up the Organization for Economic Cooperation and Development (OECD), which on average is 24.5%. 9 June 2025
Generics
The Russian pharmaceutical market, valued at around $41 billion, continues to be a magnet for Indian pharmaceutical companies. 9 June 2025
Pharmaceutical
Artificial Intelligence (AI) has rapidly evolved from a promising technology to a core enabler of innovation in the pharmaceutical industry. Today, AI is estimated to generate between $350 billion and $410 billion in annual value for pharmaceutical companies. 29 May 2025
Generics
Russian drugmaker Geropharm has received a compulsory license from the Russian state to produce a generic of Ozempic (semaglutide) developed by Denmark’s Novo Nordisk. As in case of Ozempic, Geropharm’s generics are used to treat diabetes, as well as for weight loss, reports The Pharma Letter’s local correspondent. 28 May 2025
Biotechnology
Lupus is a rare autoimmune disease characterized by chronic inflammation. It presents in four main forms: systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), drug-induced lupus, and neonatal lupus. 28 May 2025
Generics
The share of generics in the Russian pharmaceutical market is steadily growing despite the efforts of the local state to create conditions for the production of original drugs, The Pharma Letter’s local correspondent reports. 22 May 2025
Pharmaceutical
Pharmasyntez, one of Russia’s leading drugmakers, plans a significant expansion of its portfolio of innovative drugs in the short-term, according to recent statements, made by representatives of the company, reports The Pharma Letter’s local correspondent. 21 May 2025
Generics
Representatives of Russian patent unions have sent an appeal to the Russian Scientific Center for Expertise of Medical Products to provide a protocol for the compliance of Lantesens, a drug for the treatment for spinal muscular atrophy (SMA), which is produced by the Russian drugmaker Generium, a copy of the original drug Spinraza (nusinersen) from US biotech Biogen, reports The Pharma Letter’s local correspondent. 14 May 2025
Pharmaceutical
The Russian authorities are preparing for a further reduction of the share of imported drugs in the domestic public healthcare system. 13 May 2025
Generics
India has declined the UK's request to include a 'data exclusivity' clause in the proposed Free Trade Agreement (FTA), as announced on May 6, underscoring its commitment to protect its robust domestic generic drug industry. India's generic drug industry is valued at over $30 billion. 13 May 2025
Pharmaceutical
A Feature on M&A, VC investment, licensing and partnerships in the radiopharmaceuticals arena. 9 May 2025
Pharmaceutical
As the US government, under President Donald Trump, is on the verge of announcing significant new tariffs on pharmaceutical imports, Indian drug-maker stocks continue to take a hammering on the bourses. 8 May 2025
Pharmaceutical
The pharmaceutical industry in Latin America is currently facing several challenges in terms of containment of chronic non-communicable diseases, impacted by the lack of adherence to treatments and the delay in access to innovations in diagnosis, treatment, control and follow-up. 2 May 2025
Pharmaceutical
April marks Sarcoidosis Awareness Month - a timely opportunity to highlight recent advances in the treatment of this rare condition. 2 May 2025
Pharmaceutical
Shortly after Robert F Kennedy Jr was sworn in as Secretary of Health and Human Services (HHS), US President Donald Trump issued an executive order establishing the Make America Healthy Again Commission. 1 May 2025
Pharmaceutical
The Russian drugmaker Akrikhin has filed a lawsuit against UK pharma major AstraZeneca to the Moscow Intellectual Property Court asking to recognize its right to use formulas from two patents of Astra Zeneca for production of Forxiga (dapagliflozin), a drug for the treatment of diabetes and cardiovascular diseases, The Pharma Letter’s local correspondent reports. 1 May 2025
Pharmaceutical
The Russian pharmaceutical market grew up to 814 billion roubles ($10 billion) in the first quarter of 2025, 11% higher compared to the same period in 2024, according to latest data, provided by experts of the Russian research agency in the field of pharmaceutics DSM-Group and some local media reports, reports The Pharma Letter’s local correspondent. 30 April 2025
Pharmaceutical
Seeking to ensure the quality and safety of pharmaceutical products, India's regulatory bodies have intensified their crackdown on substandard and spurious drugs. The move comes at a crucial juncture as the country inches closer to establishing a comprehensive regulatory framework for over-the-counter (OTC) medications, reports The Pharma Letter’s India correspondent. 28 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze